A Phase I/II, Single and Repeat Dose, Dose Escalation Study of AV0328 Administered to Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs AV 0328 (Primary)
- Indications Bacterial infections; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Alopexx Vaccine
- 09 Apr 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2018.
- 09 Apr 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2018.
- 25 Oct 2017 According to an Alopexx Vaccine media release, the phase I portion of this trial is completed.